Counterfeit, “Natural,” and Gray-Market Sildenafil in 2025: A Major Challenge for the Legitimate Generic Industry

France’s “Viagra honey” crisis and the rise of adulterated natural aphrodisiacs

One of the most striking developments of 2025 in the European ED-drug landscape is the explosion of “Viagra honey”, also known as “love honey,” “miel aphrodisiaque,” or “miel bleu.” Though marketed as natural aphrodisiac honey, chemical analyses routinely reveal undeclared sildenafil or tadalafil, the same molecules used in prescription ED drugs. According to The Times, French authorities are seizing record quantities (tens of thousands of tons) from retail stores, shipping containers, informal markets, and online vendors.

This phenomenon is powerful not because the products contain PDE5 inhibitors but because they are sold as natural and plant-based. Consumers seeking herbal alternatives to Viagra are the primary targets, and most are unaware that these jars contain pharmaceutical-grade agents, often in wildly inconsistent doses. The health implications can be serious: unstable concentrations of sildenafil or tadalafil, combined with impurities from unregulated manufacturing, have caused reports of hypotension, palpitations, and arrhythmia. Cardiovascular specialists warn that a user who believes he is taking a botanical aphrodisiac may inadvertently combine it with nitrates or other contraindicated medications.

French regulators have responded with aggressive enforcement: surveillance at ports, seizures at customs, marketplace shutdowns, and warnings across news networks. The scale suggests a cross-border supply chain rather than isolated producers. The adulteration of a food product with undeclared pharmaceuticals also creates a unique regulatory overlap, blending food fraud, supplement fraud, and pharmaceutical crime.

For the legitimate generic industry, this trend presents a reputational risk. The molecule is identical, but the delivery vehicle, contaminated honey sold as “all-natural”, is illegal and dangerous. Consumers who fall ill often attribute their symptoms not to illicit adulteration but to “Viagra,” which blurs public understanding of what prescription sildenafil actually is. This confusion undermines trust in legal generics, even though regulated pharmaceutical products bear no resemblance to pseudo-herbal concoctions created in uncontrolled environments.

The UK’s escalating counterfeit sildenafil problem

While France deals with food-based adulteration, the United Kingdom faces a more familiar but rapidly growing threat: counterfeit sildenafil tablets. According to The Sun, sildenafil remains the most counterfeited drug in the UK, with authorities seizing 2.6 million doses of illegal or unlicensed sildenafil in 2023. Early 2025 data suggest the number will rise.

Counterfeiting thrives despite legal generics being widely available and inexpensive. Criminal organizations exploit anonymity, customer embarrassment, and the demand for ultra-low-cost products. High-quality counterfeits now mimic legitimate packaging, including foil stamping, holograms, blister prints, and QR codes. Some illegal suppliers even claim that their tablets are “Indian generics” or “EU-approved generics” to gain trust.

The medical danger is significant. Laboratory examinations of seized counterfeit tablets show:

• grossly incorrect dosages (from trace sildenafil to overdosed tablets exceeding 200%),
• contaminants or adulterants, including stimulants and unapproved analogs,
• complete absence of sildenafil despite the labeling,
• substitution with pharmacologically risky compounds.

This unpredictability, and not merely toxicity, poses the greatest risk. UK emergency departments continue to report presentations involving fainting, chest pain, priapism, and arrhythmias linked to illicit sildenafil purchased from informal online vendors.

The problem is compounded by the role of websites posing as pharmacies. Many operate outside UK jurisdiction and circumvent pharmacy regulations by hosting servers abroad. They often replicate the aesthetics of legitimate online clinics, including “doctor review” banners and fake compliance badges, creating a pharmacy impostor ecosystem. Consumers seeking convenience frequently do not differentiate between approved telemedicine platforms and illicit digital storefronts.

Since counterfeit ED drugs are sold in stigmatized markets where buyers prefer discretion, regulators face persistent difficulty reaching vulnerable consumers. Public-health campaigns continue to warn against purchasing from unverified sites, but counterfeit supply networks adapt quickly and exploit the same digital channels that legal telemedicine uses.

Gray-market “generics”: Kamagra and the illusion of legitimacy

The third major category shaping the 2025 counterfeit landscape is gray-market PDE5 products, particularly Kamagra and similar brands from unlicensed manufacturers. While not always counterfeit in the strict chemical sense (many do contain sildenafil), Kamagra is not approved in the UK or the EU. It occupies a legally ambiguous middle ground: not fake, not legal, not regulated, and sometimes chemically inconsistent.

Investigative reporting by The Sun highlights how easily Kamagra is purchased online under the illusion of being a “cheap generic.” The branding reinforces this assumption: colorful sachets, “jelly” versions, and claims of fast action make it appealing to young consumers and first-time ED-drug users. Yet these products bypass all MHRA regulatory standards and do not undergo batch testing, stability checks, or quality inspections. Some samples tested in Europe have contained contaminants or inactive filler ingredients; others have contained supratherapeutic sildenafil concentrations. Unlike counterfeits, which mimic the branding of Viagra or official generics, gray-market products like Kamagra maintain a distinctive appearance. This uniqueness can mislead consumers into believing they are legitimate international versions. Many buyers trust these products because they appear professional, come in elaborate packaging, or are sold via websites that superficially resemble telehealth clinics.

Compounding the risk is the online distribution pattern. Kamagra is heavily marketed through SEO-optimized websites, online ads, and affiliate programs that promote it as a “natural solution” or “herbal jelly,” even though the active ingredient is synthetic sildenafil. Social-media channels and messaging apps provide additional distribution routes, often with no age verification, no medical screening, and no dosage counseling.

The prevalence of Kamagra and other gray-market sildenafil variants highlights a structural problem: the boundary between counterfeit and unregulated products is often invisible to consumers. This blurs the public perception of ED medication safety and creates distrust toward the entire category of sildenafil products, regulated or not.

Implications for the legitimate generic industry and for regulatory policy

The counterfeit, adulterated, and gray-market sildenafil boom of 2025 has profound implications for legal manufacturers, regulators, and clinicians. Even though counterfeit products have no connection to approved generics, they shape the public narrative around safety, price, and trust. This creates pressure on legitimate pharmaceutical companies, who must now navigate a marketplace where the same molecule exists simultaneously in tightly regulated and completely uncontrolled forms.

Reputational contamination

The presence of adulterated honeys, counterfeit tablets, and illegal jelly formulations leads many consumers to make broad assumptions about sildenafil as a class. When someone experiences a negative health event from illicit ED products, they often attribute the harm to “Viagra” or “generics” as a whole. This creates reputational contamination that legitimate manufacturers must actively counter. They increasingly must emphasize that approved generics undergo strict GMP manufacturing, standardized dosing, and pharmacovigilance monitoring, none of which apply to counterfeit products.

Pressure on online-platform regulation

One of the clearest consequences of the counterfeit boom is regulatory tightening around digital distribution. As more consumers purchase sildenafil online, regulators now view the digital environment as both the greatest risk vector and the most efficient enforcement point. Consequently, online pharmacies and telemedicine platforms face stricter compliance requirements, including enhanced identity checks, verification of prescriber credentials, supply-chain documentation, and anti-counterfeit authentication features.

These measures protect consumers but increase operational costs for legitimate generics, even though the counterfeit problem originates entirely from unregulated sellers.

Complicated pricing expectations

Illegal and gray-market sellers distort price expectations by offering sildenafil at extremely low prices, sometimes pennies per dose. Consumers then question why regulated generics cost more, despite the vast difference in manufacturing standards, ingredient sourcing, and quality testing. Manufacturers must constantly explain that true generics are inexpensive but not as cheap as counterfeits, because counterfeits ignore safety standards, quality control, and legal obligations.

Enhanced customs and cross-border enforcement

Governments now recognize ED drugs as a major target for pharmaceutical crime. Border agents receive more training, and interdisciplinary teams collaborate more closely. Legitimate manufacturers often participate by providing authentication guidance, sharing serial-number patterns, and validating batch codes found on seized products.

The challenge of public education

A recurring strategic necessity for the generics industry is consumer education. Manufacturers of legitimate generics must clarify:

• what an approved generic is,
• how to identify a regulated pharmacy,
• why “natural” ED supplements are often adulterated,
• why gray-market “generics” are illegal,
• and how counterfeiters mimic packaging.

Transparent communication is now part of generics-sector risk mitigation, not a marketing choice.

Long-term consequences

If counterfeit volumes continue to rise, regulators may adopt stricter penalties for online illegal sellers, more aggressive takedown mechanisms for illicit platforms, enhanced serialization and tracking systems for ED medications, broader public-awareness campaigns targeting high-risk groups, tighter rules for food-supplement imports and inspections.

The legitimate generics industry supports such measures because counterfeits harm both public health and brand credibility. Yet the regulatory tightening that follows counterfeit crises tends to impose additional burdens on companies that already follow the rules.

Overall, the counterfeit crisis forces generics manufacturers to adopt a dual defensive strategy: protecting consumers from illegal products and protecting their own reputations from association with them.

References

1. The Times. (2025). Viagra honey: the illegal aphrodisiac France can’t get enough of. https://www.thetimes.co.uk/article/viagra-honey-the-illegal-aphrodisiac-france-cant-get-enough-of-pbvwtdgx3
2. The Sun. (2024). Victim of spiralling Viagra crisis warns: “I made a mistake you shouldn’t repeat”. https://www.thesun.co.uk/health/36931249/victim-spiralling-viagra-crisis-mistake-dont-repeat
3. The Sun. (2023). Sex, Viagra jelly & Kamagra crime: inside the UK’s illegal ED drugs scene. https://www.thesun.co.uk/health/34333922/sex-viagra-jelly-kamagra-crime